cero therapeutics board of directors

This website uses cookies so that we can provide you with the best user experience possible. Board of Directors Her expertise is in novel and emerging modalities in oncology, including cell therapy. Chair of the board, has served on our board of directors since our conversion to a corporation in January 2009 and as our Chair since June 2013, and prior to that was a director of Regulus Therapeutics LLC since July 2008.Since 1994, Dr. Papadopoulos has served as a director and, since 1998, as In addition, from 2015 to 2018, Dr. Dissanaike served as Interim Director of the Timothy J. Harnar Burn Center at University Medical Center in Lubbock, Texas (UMC). Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firms Medical Supplies and Devices team, from January 2014 to June 2014. CERo Therapeutics - Overview, News & Competitors | ZoomInfo.com Cero Therapeutics - Crunchbase Company Profile & Funding Previously, he was an observer on the board of Nkarta Therapeutics, a NK-CAR cancer cell therapy company. He obtained an MBA from Cornell University. This role will support CERos Research, Process Development, Quality, Regulatory and Clinical Research organizations. Prior to Orchard, Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics (NASDAQ: PTCT), where he helped it evolve into a commercial company with a global footprint, including the successful launch of two rare disease therapies. John G. Houston, Ph.D. Chairperson, Chief Executive Officer, and President. Chief Medical Officer at Infectious Disease Research Institute (IDRI), and Co-Director of University of Washington/Fred Hutch Center for AIDS Research. Most recently, Dr. Akopian served as Vice President of Quality at Nitto Avecia Pharma Services, responsible for Quality Assurance and Quality Systems compliance to regulatory standards for custom development and commercial product support. Ms. Rodriguez has served as Chief Commercial Officer of Ardelyx, Inc. since May 2020. Prevail Therapeutics Announces Appointment of William The boards of directors of both CERo and PBAX Lorem ipsum dolor sit amet consectetur adipisicing elit. Dr. Corey is a member and past President of the Fred Hutchinson Cancer Research Center, a member of the National Academy of Medicine and a Co-founder of Juno Therapeutics, Vir Biotechnology, and Immune Design Corporation. Over the course of her 13-year tenure at Genentech, she managed multiple projects from early stage to launch, including the mAbs Perjeta and Tecentriq and the ADC polatuzumab vedotin. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies from outside as well, we will achieve the best results. Louis W. The companys core technology platform engineers T cells to express immune receptors called chimeric engulfment receptors (CERs) that enable T cells to target, induce cellular damage, uptake tumor antigen, and remove tumor cells. Dr. Pomerantz is Board Certified in both internal medicine and infectious diseases. Since 2013, Mr. Johnson has served as a director of La Jolla Pharmaceutical Company and a director of Mirati Therapeutics, Inc. Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and global leadership, including driving the successful build of multiple biotech companies, predominantly in the field of rare or specialty diseases. in Engineering from the Southern College of Technology (now Southern Polytechnic State University). Prior to joining Viracta, Mr. Rothera served as President and CEO of Silence Therapeutics (NASDAQ: SLN), a clinical-stage organization focused on developing RNA therapies for hematology, cardiovascular and rare diseases. Previously, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from February 2018 to June 2020. This integrated approach draws on recent advances in molecular immunology and a deeper understanding of cell signaling downstream of specialized receptors that cooperate to ingest and eliminate dangerous cells and pathogens. CERos CER-T technology instructs immune cells to engage novel and complementary tumor cell clearance pathways designed to enable deeper and more sustained responses against broad classes of tumors. Dr. Vezan joins CERo from Kite, a Gilead Company, where he spent the last four years in cell therapy clinical development, most recently as Executive Director of Clinical Development. Stanley Riddell, MD, is Head of Research and Development at Lyell Immunopharma, Inc. and is a Member at the Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington. Professor and Head of the Lymphoma Program at Ohio State University, and member of Blood and Marrow Transplant Clinical Trials Network. Dr. Sorensen serves on the boards of directors of several private companies including Esanik Therapeutics, Medsyn Biopharma and PlanetVerify Ltd. Previously, Mr. Chevallard served as the Chief Financial Officer and principal financial officer at Regulus Therapeutics from May 2017 to July 2019. Background: Compared with other CAR T-cell products, axicabtagene ciloleucel (axi-cel) had a shorter median wait time from leukapheresis to infusion, referred to as vein-to-vein time (real-world: axi-cel, 28 d vs tisagenlecleucel, 45 d; clinical trial: lisocabtagene maraleucel, 37 d; Riedell et al.Transplant Cell Ther 2022; Abramson et From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. and, from 2009 to 2010, as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., ultimately serving as Chief Financial Officer and Senior Vice President of Operations. with high honors in Biochemistry from the University of California at Berkeley. He received his PhD from the Massachusetts Institute of Technology. WebMr. CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Patric Nelson, MBA,joined Viracta from Esperion Therapeutics, where he served as Vice President, Business Development and Alliance Management. Prior to Tolmar, from 1990 to 2014, Ms. Rodriguez held various positions of increasing responsibility at Abbott Laboratories (NYSE: ABT), most recently as Divisional Vice President of Global Marketing, where she led the global marketing function for an international portfolio of Abbott products. Lyell, with their advanced T-cell capabilities, is an ideal partner for CERo. About CERos CER-T PlatformRecently, cell-based therapies have emerged as new tools in the fight against cancer. in Molecular Biophysics and Biochemistry from Yale University and his M.Sc. Sharmila Dissanaike, M.D., FACS, FCCM has served as a director of Heron since September 2021. as Senior Vice President and Head of Translational Medicine. "With CER T and novel CAR T products, we see a vast opportunity to improve upon and optimize cell therapy to increase the curative potential and improve the safety profile with this remarkable therapeutic approach. Christian Waage has served as a director of Heron since 2016. shareholders and to oversee the management of the Company's business. Previously, Mr. Brown served as Vice President and Deputy General Counsel at Evofem Biosciences, Inc. (EVFM). He served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018, a director of Adamis Pharmaceuticals Corporation from 2011 to 2014 and a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. Dr. Mackall also contributed to the invention of the CD19/22 bispecific and bicistronic CARs and led the first two clinical trials of the CD19/22 bispecific-CAR at Stanford. million verified professionals across 35 million companies. Dr. Faller received his medical degree from the Harvard University where he also served on the faculty of Brigham and Womens Hospital, Dana-Farber Cancer Institute, and Boston Childrens Hospital. Jun 23 2023 - Previously, he served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Previously, Cheryl was the Vice President of Regulatory Affairs at Peloton Therapeutics where she facilitated the successful acquisition of their HIF2- inhibitor (belzutifan) by Merck. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In addition, he served as the President, Chief Executive Officer and Chairman of the Board of Seres Therapeutics from 2014-2019, where he continues to serve as Senior Advisor to its Board of Directors. Mr. Our team possesses deep, cross-functional experience and shares a longstanding commitment to developing new medicines to benefit cancer patients. Prior to becoming an investor, Dr. Lukatch worked as a strategy consultant with McKinsey & Company and was co-founder and CEO of AutoMate Scientific, a biotechnology instrumentation company. To view CERo Therapeuticss complete valuation and funding history, request access, To view CERo Therapeuticss complete cap table history, request access, To view CERo Therapeuticss complete patent history, request access, Youre viewing 2 of 4 executive team members. He has been a founder, investor, senior executive, and board member of a number of companies at different stages in their corporate growth, including Shucks Auto Supply, Quality Food Centers, J Crew, and Anixter International. She started her career at Johnson & Johnson as a research associate, and then moved to Aviron/Medimmune Vaccines as an associate scientist before joining Genentech. Parvus Therapeutics Board of Directors ADC Therapeutics The Special Committee is comprised of independent directors Simon Dumesnil and Alfred Novak. He is co-founder of Hamptons United, a charity started as a result of the coronavirus pandemic to help support local charities on the east end of Long Island. Mr. Morgan also currently serves on the board of directors of Alimera Sciences, Inc., where he serves as a director and member of the companys Compensation Committee, and Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as a director and chair of the companys audit committee. from the University of San Diego School of Law and a B.A. Prior to joining Secura Bio, Inc., Ms. Burcar held various finance and accounting roles in life science and medical device companies including Synthetic Genomics, Inc. and Ortho Organizers. She holds an M.B.A from New York Universitys Stern School of Business and a B.A. Dr. Mackalls lab invented the CD22-CAR (Haso, Blood 2014) which is the focus of CARGOs lead clinical candidate, and she played a leading role in the NCI clinical trial of the CD22-CAR (Fry, Nat Med 2018; Shah, JCO, 2020). This approach effectively unites the anti-tumor attributes of both innate and adaptive immune responses into a single T cell product. She also holds BA and BS degrees in Immunology and Economics from the University of California, Berkeley. She received her Bachelor of Accountancy from the University of San Diego and her M.B.A. from University of California, San Diego and is also a Certified Public Accountant in the state of California. Mr. Rossi, before joining CERo, led the cell therapy clinical pharmacology team at Kite, a Gilead Company, supporting the clinical development and global approvals of YESCARTA and TECARTUS. He is a Pharma and Biotech Executive with over 15 years of experience and leadership in cancer drug discovery, translational oncology and external innovation. CERo Therapeutics Company Profile | Management and Abe was also the founder of Aurora Medical, a molecular diagnostics testing services company. The Board has concluded that Mr. Johnson should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management. {{ userNotificationState.getAlertCount('bell') }}. In addition to her regulatory responsibilities, she served as Project Team Leader for XTANDI from 2015-2016. Prior to its acquisition by Celgene Corporation in 2015, he served as Senior Vice President and General Counsel of Receptos, Inc. From 2012 through its acquisition by Vista Equity Partners Management, LLC in 2013, Mr. Waage served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, he served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Remus and John will be instrumental to our next stage of growth as we look to test this approach in the clinic and further develop the platform.". WebCERo Therapeutics Profile and History. CERo Therapeutics, Inc.Daniel Corey, MDdcorey@cero.bio1-650-491-9604. Dr. Dissanaike is a clinically active trauma, burn and acute care surgeon who has won over 50 awards for clinical, academic and research excellence and service during her career. May 15, 2023. Proceeds from the financing are being used to expand start-up operations and advance the companys proprietary CER-T technology platform into the clinic. Members of the Board of Directors include: In addition, providing further scientific expertise is: CERo also has an internal team of about a dozen researchers. Upon closing of the transaction, anticipated to occur in the second half of 2023, the combined company will be named CERo Therapeutics Holdings, Inc. and will be led by CERo and PBAXs founding members, including Daniel Corey, M.D., CERos CEO, Chris Ehrlich, PBAXs CEO, and Brian G. Atwood, the Chairman of PBAX. Lyell is focused on advancing the science of T-cell differentiation, functionality, and target specificity in order to develop curative treatments for human disease. WebCompany. CERos technology combines multiple forms of tumor cell clearance and introduces them into single cells to vastly expand their therapeutic potential, said Daniel Corey, MD, Co-founder and Chief Executive Officer of CERo. Ms. Rodriguez has more than 25 years of experience in the biopharmaceutical industry, serving in senior commercial and operational management roles. CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. CERo Therapeutics, Inc., is a privately held biopharmaceutical company pioneering cell-based therapies that incorporate multiple forms of tumor clearance into single cells. Dr. Gruia currently serves as an Independent Board Director at Tessa Therapeutics, TScan Therapeutics, and Molecular Templates. Robyn Hatton Head of Human Resources. Policy, Assist with optimization and further development of lentiviral vector platform and quality control strategy within a cross-functional team to support multiple cell therapy programs and pipeline activities, Manage the day to day research activities of the R & D vector core laboratory, Support the management team by providing technical leadership within the organization on lentiviral vector biology, construction, process development and manufacturing, Assist with oversight of vector transfers to CMOs, Generate internal technical documents, SOPs and presentations for cross-functional communication, Drafting, reviewing, approving, and supporting regulatory filings, including IND amendments, BLAs, and regulatory responses, Assist in the development of SOPs, justification of specifications, quality control, and sampling plans in support of cell line banking and lentiviral vector stocks, Develop and lead strong collaborative relationships with internal and external collaborators, Develop and mentor a group of diverse scientists and research associates to enable cross-functional collaboration, career development, and leading innovation, Preferred BA/BS: 15 years or MA/MS: 13 years or PhD: 10 years post graduate work, (PhD in Virology, Molecular Biology or equivalent with 7+ years of proven experience in applied virology including lentiviral vector development), Proficient in ICH, FDA, EMA, and JP regulations and guidance, Expertise in USP, EP, JP, etc. info@herontx.com, IITs, Grants, Sponsorships, and Contributions. Lyell, with their advanced T-cell capabilities, is an ideal partner for CERo. CERo Human Resources leads recruitment and employment for CERo. WebOur Board of Directors bring diverse experience and significant expertise to guide our path forward. Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen (NASDAQ: AMGN) while studying at Ecole Suprieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his PhD from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX: MOLN). Mr. Darcy also served as a director and audit committee member of Forte Biosciences, Inc. from June 2020 through May 2021 and currently serves as a director and chairman of the audit committee of Lytx, Inc., a privately-held technology company.
Stamford Catholic High School In Memoriam, What Is Cr Zoning In Cabarrus County, Houses For Sale In Seraleng, Rustenburg, Kansas City Airport To Des Moines, Articles C